This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hoskins, P.J. Articles by Lee, N. Search for Related Content PubMed PubMed Citation Articles by Hoskins, P.J. Articles by Lee, N. Social Bookmarking                            What's this?

Small-Cell Carcinoma of the Cervix: Fourteen Years of Experience at a Single Institution Using a Combined-Modality Regimen of Involved-Field Irradiation and Platinum-Based Combination Chemotherapy

From the Division of Medical Oncology, Division of Radiation Oncology, and Cancer Control Research, British Columbia Cancer Agency, Vancouver and Fraser Valley Clinics, British Columbia, Canada.

Address reprint requests to Paul J. Hoskins, MD, British Columbia Cancer Agency, 600 West 10th Ave, Vancouver, BC, Canada, V5Z 4E6; e-mail: phoskins{at}bccancer.bc.ca.

Purpose: To determine the efficacy and toxicity of a combined-modality regimen of irradiation with platinum-based combination chemotherapy in small-cell carcinoma of the cervix (SCCC).

Patients and Methods: Thirty-four patients with SCCC were seen and treated at the British Columbia Cancer Agency between May 1988 and November 2002. Two protocols were used, SMCC (May 1988 to December 1995) and SMCC2 (January 1996 to November 2002). Both protocols used cisplatin, etoposide, and involved-field irradiation (essentially pelvis plus or minus para-aortics) with concurrent chemotherapy. In addition, SMCC2 included carboplatin and paclitaxel, and the para-aortics were irradiated routinely.

Results: Thirty-one patients received either SMCC (n = 17) or SMCC2 (n = 14), and three patients did not (disease too extensive, n = 1; patient refusal, n = 1; and alternative regimen, n = 1). For the 31 patients treated on one of the protocols, the 3-year overall and failure-free survival (FFS) rates were 60% and 57%, respectively. The results were equivalent for SMCC and SMCC2. Radiologic stage was the only independent predictor for FFS (80% at 3 years for stage I and II patients v 38% at 3 years for stage III and IV patients). Distant failure (28%) was the most common cause of failure, with local failure occurring in 13% of patients. The switch to SMCC2 did not improve efficacy but did lessen the toxicity.

Conclusion: SCCC can be successfully treated in approximately 55% of patients with a combination of irradiation and platinum-based chemotherapy. Disease extent predicts for chance of curability.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. BIFULCO, V. D. MANDATO, P. GIAMPAOLINO, R. PICCOLI, L. INSABATO, N. DE ROSA, and C. NAPPI Small Cell Neuroendocrine Cervical Carcinoma with 1-Year Follow-up: Case Report and Review Anticancer Res, February 1, 2009; 29(2): 477 - 484. [Abstract] [Full Text] [PDF]

				J.-M. Lee, K.-B. Lee, J.-H. Nam, S.-Y. Ryu, D.-S. Bae, J.-T. Park, S.-C. Kim, S.-D. Cha, K.-R. Kim, S.-Y. Song, et al. Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study Ann. Onc., February 1, 2008; 19(2): 321 - 326. [Abstract] [Full Text] [PDF]

				T. R. Kataoka, Y. Tsukamoto, M. Matsumura, A. Miyake, S. Kamiura, S. Ishiguro, and Y. Nishizawa Expression of p21Cip1/Waf1 and p27Kip1 in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix International Journal of Surgical Pathology, January 1, 2008; 16(1): 11 - 15. [Abstract] [PDF]

				J. D. Hainsworth, D. R. Spigel, S. Litchy, and F. A. Greco Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study J. Clin. Oncol., August 1, 2006; 24(22): 3548 - 3554. [Abstract] [Full Text] [PDF]

				J. H. Kim, S.-H. Lee, J. Park, H. Y. Kim, S. I. Lee, E. M. Nam, J.-O. Park, K. Kim, C. W. Jung, Y.-H. Im, et al. Extrapulmonary Small-cell Carcinoma: a Single-institution Experience Jpn. J. Clin. Oncol., May 1, 2004; 34(5): 250 - 254. [Abstract] [Full Text] [PDF]